Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Virtual Care to Improve Heart Failure Outcomes (VITAL-HF)

NCT05602454 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to evaluate how safe and effective a remote, digital intervention is that helps clinicians use and optimally adjust heart failure medications, compared to usual care medication use and adjustment, in participants with heart failure with reduced ejection fraction

Interventions

  • OTHER Digital Heart Failure Medication Titration

Study Locations (7)

Florida

  • Cardiovascular Institute of Northwest Florida — Panama City

Indiana

  • Ascension St. Vincent — Indianapolis

Kansas

  • The University of Kansas Medical Center — Kansas City

Minnesota

  • Minneapolis Heart Institute Foundation — Minneapolis

Missouri

  • Saint Luke's Health Systems — Kansas City

North Carolina

  • Duke University — Durham

Ohio

  • Cleveland Clinic — Cleveland

Trial Details

FieldValue
Enrollment Target 178 participants
Start Date 2022-12-02
Est. Completion 2025-03-05
Phase NA

Sponsor

Duke University

1,129 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05602454

The ClinicalTrials.gov registry entry for NCT05602454 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,129 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Heart Failure With Reduced Ejection Fraction appearing as the primary indexed condition, and to 1 intervention — of which Digital Heart Failure Medication Titration is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05602454 reports 7 study locations spanning 7 distinct geographic areas — top geographies include Florida, Indiana, Kansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05602454 about?

NCT05602454 is a clinical study titled "Virtual Care to Improve Heart Failure Outcomes (VITAL-HF)". The purpose of this study is to evaluate how safe and effective a remote, digital intervention is that helps clinicians use and optimally adjust heart failure medications, compared to usual care medication use and adjustment, in participants with heart failure with reduced ejection fraction

What is the current status of trial NCT05602454?

This trial is currently completed. It is a NA study. The enrollment target is 178 participants. The study started on 2022-12-02. Estimated completion is 2025-03-05.

What conditions does trial NCT05602454 study?

This clinical trial studies the following conditions: Heart Failure With Reduced Ejection Fraction. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05602454?

The interventions under investigation include: Digital Heart Failure Medication Titration (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05602454?

This trial is sponsored by Duke University, which has 1,129 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05602454 being conducted?

This trial has 7 study locations across Florida, Indiana, Kansas, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial